METHOD FOR ASSESSING THE RISK OF UNFAVOURABLE OUTCOME OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS Russian patent published in 2023 - IPC G01N33/68 G01N33/49 G01N33/53 

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely, to endocrinology and cardiology, and can be used to assess the risk of an unfavourable outcome of acute myocardial infarction in patients with type 2 diabetes mellitus. The patient undergoes clinical examination, factors of immune response are determined — C-reactive protein, interleukin-6 and -10, tumour necrosis factor-α. The sex of the patient, the indicators of interleukin-8 and highly sensitive C-reactive protein, the absolute lymphocyte count, the RBC distribution width, the average platelet volume, and the relative platelet large cell count are taken into account, and the value of the Garkavi adaptation index is set. After that, the coefficients F1, F2, F3, and F4 are determined by the formulas: F1=-129.762+5.086·X1+0.176·X2-0.204·X3-0.072·X4+11.953·X5+0.901·X6+4.364·X7+9.055·X8+6.694·X9+0.421·X10+4.363·X11; F2=-119.368+4.077·X1+0.185·X2+0.005·X3-0.458·X4+12.243·X5+0.630·X6+1.926·X7+8.944·X8+6.146·X9+0·568·X10+4.334·X11; F3=-126.821+2.757·X1+0.335·X2-0.111·X3-0.428·X4+18.952·X5+0.485·X6+2.505·X7+9.653·X8+5.452·X9+0.706·X10+3.693·X11; F4=-114.365+6.966·X1+0.017·X2-0.092·X3+0.073·X4+5.310·X5+0.549·X6+2.933·X7+6.175·X8+13.719·X9-1.396·X10+1.113·X11, wherein: X1 is sex: male - 1, female - 2; X2 is the level of interleukin-6 in serum, pg/ml; X3 is the level of interleukin-8 in serum, pg/ml; X4 is the level of interleukin-10 in serum, pg/ml; X5 is the level of tumour necrosis factor-α in serum, pg/ml; X6 is the level of highly sensitive C-reactive protein in serum, mg/l; X7 is the absolute lymphocyte count, 10⁹/l; X8 is the RBC distribution width, %; X9 is the average platelet volume in femtolitres, fl; X10 is the relative platelet large cell count, %; X11 is the Garkavi adaptation index, CU. If F1 is greater than F2, F3, and F4, the risk is assessed as low. If F2 is greater than F1, F3, F4, and if F3 is greater than F1, F2, F4, the risk is assessed as medium. If F4 is greater than F1, F2, and F3, the risk of an unfavourable outcome of myocardial infarction in patients with type 2 diabetes mellitus is assessed as high.

EFFECT: possibility of early assessment (in the first day of the disease) of the outcome of acute myocardial infarction with a rise of a ST segment of the electrocardiogram in patients with type 2 diabetes mellitus, both in men and in women, due to a clinical examination of the patient and determination of the factors of immune response and parameters of blood cells.

1 cl, 4 ex